Doctors test new drug combo to shrink tumors before sarcoma surgery
NCT ID NCT01746238
Summary
This early-stage study is testing the safety of a three-part treatment given before surgery for soft tissue sarcoma. The treatment combines a targeted drug (bevacizumab), a chemotherapy (doxorubicin), and radiation therapy. The main goal is to find the highest safe dose of bevacizumab in this combination to try to shrink tumors and prevent the cancer from coming back after surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.